SOUTH SAN FRANCISCO, Calif., Aug. 2, 2020 /PRNewswire/ -- VistaGen Therapeutics, Inc. (Nasdaq: VTGN), a biopharmaceutical company developing new generation medicines for anxiety, depression and other central nervous system (CNS) disorders, today announced the pricing of its underwritten public offering of 15,625,000 shares of its common stock at a public offering price of $0.80 per share. Gross proceeds from the offering, before underwriting discounts and commissions and estimated offering expenses, are expected to be $12.5 million. In addition, VistaGen has granted the underwriter a 45-day option to purchase up to an additional 2,343,750 shares of common stock at the per share public...
|
